LegisTrack
Back to all bills
HR 5197119th CongressIn Committee

Protect Beneficiaries from Middlemen Act

Introduced: Sep 8, 2025
HealthcareSocial Services
Standard Summary
Comprehensive overview in 1-2 paragraphs

The Protect Beneficiaries from Middlemen Act would overhaul how Medicare Part D plans determine patient cost sharing for covered drugs. Starting with plan years beginning in 2027, the Act would cap a beneficiary’s monthly cost-sharing amount for a Part D drug at the drug’s net price (or, if lower, the applicable cash price) rather than the current cost-sharing levels that can be influenced by rebates and middlemen. Net price is defined as the price paid by the plan for the drug (including the beneficiary’s cost sharing), minus rebates or other remuneration received by the plan. The bill also requires that low-income copayments for Part D drugs not exceed this net price cap and creates a GAO evaluation to assess compliance, enforcement, and transparency. In short, the bill seeks to reduce or cap out-of-pocket costs for Part D beneficiaries by tying cost sharing to the actual net price paid by the plan, and it imposes oversight and future reporting to Congress on how well the approach is working and how to improve it.

Key Points

  • 1Establishes a new limit on Part D cost sharing: for plan years beginning on or after January 1, 2027, a month’s supply of a covered Part D drug dispensed by a pharmacy cannot have cost sharing higher than the plan’s average net price for that drug (or the lower applicable cash price), prior to reaching the out-of-pocket threshold.
  • 2Net price and cash price definitions:
  • 3- Applicable cash price: the price a pharmacy would charge a person without health coverage under federal programs or other specified coverage.
  • 4- Average net price: the average amount paid under the plan for a drug (including member cost sharing) minus rebates or other remuneration the plan receives for that drug.
  • 5Conforming change for low-income beneficiaries: for plan year 2027 and later, the copayment for a covered Part D drug for low-income individuals cannot exceed the net price cap.
  • 6GAO oversight: requires a GAO report by January 1, 2029 analyzing compliance, enforcement, and recommendations for better enforcement and public disclosure.
  • 7Scope within Part D: the cost-sharing cap applies to a supply dispensed by a pharmacy and is designed to function within the existing deductible and out-of-pocket thresholds of Part D.

Impact Areas

Primary group/area affected:- Medicare Part D beneficiaries, especially those with high drug costs or significant reliance on monthly prescriptions, who could see lower out-of-pocket costs if their plan’s net price is lower than current cost-sharing.Secondary group/area affected:- Part D plan sponsors, including insurers and their pharmacy benefit managers (PBMs), which would need to calculate and apply cost-sharing based on net price, requiring potential administrative system changes and data sharing with plans to determine average net price and applicable cash price each plan year.- Pharmacies, which would implement the cost-sharing determinations at the point of sale according to the plan’s net price calculation.Additional impacts:- Drug manufacturers and the broader drug pricing ecosystem may experience changes in how rebates and remuneration influence patient cost sharing, potentially affecting rebate strategies and formulary decisions.- Increased need for transparency and public awareness of pricing mechanics due to GAO reporting and disclosure requirements.- Possible changes to incentives within the Part D program and to overall drug affordability strategies if the net price cap affects plan design or negotiation dynamics.
Generated by gpt-5-nano on Oct 8, 2025